Thiogenesis Therapeutics Corp
Thiogenesis Therapeutics Corp is a clinical-stage biotech company based in Toronto, specializing in the development of novel thiol compounds that exhibit strong antioxidant and anti-inflammatory properties. Their lead compound, TTI0102, aims to address inherited and acquired mitochondrial diseases, including metabolic disorders such as type 2 diabetes and cardiovascular disease, by enhancing intracellular cysteine levels and promoting glutathione synthesis.
The company is focused on pediatric diseases characterized by oxidative stress and currently has plans to initiate three human efficacy trials in collaboration with leading research institutions. Thiogenesis Therapeutics has engineered its proprietary compounds to overcome historical challenges associated with thiol-based drugs, including short half-life and gastrointestinal side effects, demonstrating promising tolerability in early human studies.
Generated from the website
Also at this address
You might also like
Partial Data by Infogroup (c) 2024. All rights reserved.